Clinical Outcomes and Budget Impact of Cobas® Egfr Mutation Test Versus Sanger Sequencing in the Treatment of Locally Advanced or Metastatic Nsclc- A United States Payer Perspective
Abstract
Authors
N. Poulios D. Hertz M. Gavaghan